Upcoming speaking engagement: "Rare Disease Studies: How to Run Successful Programs" http://xtalks.com/rare-disease-ultra-rare-disease-studies.ashx

Head, Global Clinical Operations - Cambridge @ Global Head for Cambridge Clinical Operations staff supporting clinical programs to proof of concept (i.e., Translational Medicine) and post-proof of concept clinical trials in ultra-rare diseases. From August 2012 to Present (3 years 5 months) Project Leader, Clinical Sciences and Operations @ Global, Cross-functional Project Leader for a Janus Kinase 2 (JAK-2) Inhibitor -- one of the newer molecular targets of cancer treatment being evaluated for myelofibrosis, which is a rare, and life-threatening malignant hematologic disease. Responsible for the portfolio of Sanofi’s JAK2 clinical projects for this indication and future product extensions. From September 2011 to July 2012 (11 months) Head of Global Clinical Operations, Transplant Oncology @ Global Therapeutic Area Liaison with business unit and development teams to execute Global Development Plans according to business strategy and generate data for regulatory applications. Directed ~35 global direct-line staff and contractors in clinical operations for Transplant Oncology; 9 products in all stages of development and out-license and co-development collaborations. Provided senior oversight of clinical operations of Phase I - IV trials through relationships with key opinion leaders, vendors, and external consultants. From July 2008 to September 2011 (3 years 3 months) Senior Director, Clinical Research, Biosurgery @ From February 1998 to July 2008 (10 years 6 months) Associate Director, Medical Marketing @ From August 1994 to February 1998 (3 years 7 months) Manager, Clinical Research @ From February 1988 to August 1994 (6 years 7 months) Operations Manager @ From August 1986 to December 1987 (1 year 5 months) Research Associate @ From 1978 to 1979 (1 year)

MAS, Business @ The Johns Hopkins University - Carey Business School From 1987 to 1989